Dead space ratio as a tool in nitric oxide weaning: a study in pulmonary hypertensive disease

Cardiol Young. 2022 Oct;32(10):1603-1607. doi: 10.1017/S1047951121004662. Epub 2021 Dec 9.

Abstract

Objectives: To describe the association between successful weaning of inhaled nitric oxide and trends in dead space ratio during such weans in patients empirically initiated on nitric oxide therapy out of concern of pulmonary hypertensive crisis.

Patients: Children in a cardiac intensive care unit initiated on inhaled nitric oxide out of clinical concern for pulmonary hypertensive crisis retrospectively over 2 years.

Measurements and main results: Twenty-seven patients were included, and nitric oxide was successfully discontinued in 23/27. These patients exhibited decreases in dead space ratio (0.18 versus 0.11, p = 0.047) during nitric oxide weaning, and with no changes in dead space ratio between pre- and post-nitric oxide initiation (p = 0.88) and discontinuation (p = 0.63) phases. These successful patients had a median age of 10 months [4.0, 57.0] and had a pre-existent diagnosis of CHD in 6/23 and pulmonary hypertension in 2/23. Those who failed nitric oxide discontinuation trended with a higher dead space ratio at presentation (0.24 versus 0.10), were more likely to carry a prior diagnosis of pulmonary hypertension (50% versus 8.7%), and had longer mechanical ventilation days (5 versus 12).

Conclusions: Patients empirically placed on nitric oxide out of concern of pulmonary hypertensive crisis and successfully weaned off showed unchanged or decreased dead space ratio throughout the initiation to discontinuation phases of nitric oxide therapy. Trends in dead space ratio may aid in determining true need for nitric oxide and facilitate effective weaning. Further studies are needed to directly compare trends between success and failure groups.

Keywords: Pulmonary hypertension; dead space fraction; inhaled nitric oxide.

MeSH terms

  • Administration, Inhalation
  • Child
  • Humans
  • Hypertension, Pulmonary* / drug therapy
  • Infant
  • Nitric Oxide / therapeutic use
  • Pulmonary Arterial Hypertension*
  • Retrospective Studies

Substances

  • Nitric Oxide